Skip to content
Screener

R&D at other companies

Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.88M+61.5%
Bausch + Lomb logo
Bausch + LombBLCO
$114M+18.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$66.21M+54.5%
Opko Health logo
Opko HealthOPK
$33.17M+9.3%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$163M+14.0%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$31.01M+98.9%

Segments

By segment

See full
Branded$5.62M+182%
Compounding$210K-6.3%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.49B+22.8%
Enterprise value$1.7B+5.6%
P/S5.5×+0.2×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Harrow’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-022254
Line item2026 / For the Three Months Ended March 31,2025 / For the Three Months Ended March 31,
Gross profit27,045,00032,307,000
Operating expenses:
Selling, general and administrative43,230,00040,513,000
Research and development5,895,0003,026,000
Total operating expenses49,125,00043,539,000
Loss from operations(22,080,000)(11,232,000)
Interest expense, net(5,497,000)(6,548,000)
Loss before income taxes(27,577,000)(17,780,000)

Item 1. Financial Statements (unaudited) Item

FAQ

What is Harrow's R&D?
Harrow (HROW) reported R&D of $5.9M in Q1 2026.
How has Harrow's R&D changed year-over-year?
Harrow's R&D increased by 94.8% year-over-year, from $3.03M to $5.9M.
What is the long-term trend for Harrow's R&D?
Over 4 years (2021 to 2025), Harrow's R&D has grown at a 17.2% compound annual growth rate (CAGR), from $11.08M to $20.94M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Harrow's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude